Natalizumab (Tysabri) for relapsing multiple sclerosis.
Natalizumab (Tysabri), a selective adhesion molecule inhibitor, decreases the number of relapses and new brain lesions in patients with MS. Administered IV every 4 weeks, it is usually well tolerated, but anaphylaxis can occur and persistent neutralizing antibodies were reported in 6% of patients. No comparisons to other MS treatments and no data concerning its effect on progression of disability are currently available.